Davis, Jessie R.
Wang, Xiao
Witte, Isaac P. http://orcid.org/0000-0002-3879-0306
Huang, Tony P. http://orcid.org/0000-0003-2904-830X
Levy, Jonathan M. http://orcid.org/0000-0002-8061-7953
Raguram, Aditya
Banskota, Samagya
Seidah, Nabil G. http://orcid.org/0000-0001-6503-9342
Musunuru, Kiran http://orcid.org/0000-0003-3298-0368
Liu, David R. http://orcid.org/0000-0002-9943-7557
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (UG3AI150551, U01AI142756)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118062)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
Howard Hughes Medical Institute (Liu Investigatorship)
Bill and Melinda Gates Foundation (Liu Grant)
Article History
Received: 18 January 2022
Accepted: 19 June 2022
First Online: 28 July 2022
Change Date: 5 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41551-022-00934-x
Competing interests
: J.R.D., J.M.L., I.P.W., T.P.H. and D.R.L. have filed patent applications on this work through the Broad Institute. K.M. is a consultant and equity holder of Verve Therapeutics and Variant Bio. D.R.L. is a consultant and equity holder of Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine, and Nvelop Therapeutics, companies that use or deliver gene editing or genome engineering agents. The other authors declare no competing interests.